CN104169295B - 突变的慢病毒env蛋白及其用作药物的用途 - Google Patents

突变的慢病毒env蛋白及其用作药物的用途 Download PDF

Info

Publication number
CN104169295B
CN104169295B CN201280060076.2A CN201280060076A CN104169295B CN 104169295 B CN104169295 B CN 104169295B CN 201280060076 A CN201280060076 A CN 201280060076A CN 104169295 B CN104169295 B CN 104169295B
Authority
CN
China
Prior art keywords
seq
protein
mutated
pharmaceutical composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280060076.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104169295A (zh
Inventor
T·梅德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guo Jiakeyanzhongxin
Gustavus Institute
Thackeray Paris, University of
Viroxis SAS
Original Assignee
Gustavus Institute
Universite Paris Sud
Viroxis SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gustavus Institute, Universite Paris Sud, Viroxis SAS filed Critical Gustavus Institute
Publication of CN104169295A publication Critical patent/CN104169295A/zh
Application granted granted Critical
Publication of CN104169295B publication Critical patent/CN104169295B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280060076.2A 2011-12-07 2012-12-07 突变的慢病毒env蛋白及其用作药物的用途 Active CN104169295B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306625.2 2011-12-07
EP11306625 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (2)

Publication Number Publication Date
CN104169295A CN104169295A (zh) 2014-11-26
CN104169295B true CN104169295B (zh) 2020-07-28

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280060076.2A Active CN104169295B (zh) 2011-12-07 2012-12-07 突变的慢病毒env蛋白及其用作药物的用途

Country Status (16)

Country Link
US (1) US9682137B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2788372B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP6415324B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102059918B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104169295B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012350258B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014013704B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2856180C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2788372T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2748864T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL232926B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014CN04927A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX350689B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2654673C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013083799A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201403617B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351247B2 (en) * 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
CA3204201A1 (en) 2021-01-13 2022-07-21 Thierry Heidmann Measles-hiv or measles-htlv vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095442A1 (en) * 2004-03-30 2005-10-13 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
CA2520768A1 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
ES2572132T3 (es) 2004-08-17 2016-05-30 Roussy Inst Gustave Nef del VIH mutada para modular la inmunidad
RU2426788C1 (ru) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Генетические конструкции для антивич-терапии

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095442A1 (en) * 2004-03-30 2005-10-13 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Immunosuppressive peptide of HIV-1: Functional Domains and Immune Response In AIDS Patients;Denner J et al.,;《AIDS》;19940801;第8卷(第8期);1063-1072 *

Also Published As

Publication number Publication date
CA2856180C (en) 2022-09-06
KR102059918B1 (ko) 2020-02-11
IL232926B (en) 2019-01-31
BR112014013704A2 (pt) 2021-02-17
DK2788372T3 (da) 2019-10-14
RU2014127521A (ru) 2016-02-10
CN104169295A (zh) 2014-11-26
WO2013083799A1 (en) 2013-06-13
MX350689B (es) 2017-09-13
IN2014CN04927A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-18
KR20140116091A (ko) 2014-10-01
RU2654673C2 (ru) 2018-05-21
AU2012350258A8 (en) 2014-07-17
MX2014006744A (es) 2014-12-08
JP2015505836A (ja) 2015-02-26
ZA201403617B (en) 2015-07-29
EP2788372B1 (en) 2019-07-10
EP2788372A1 (en) 2014-10-15
JP6415324B2 (ja) 2018-10-31
CA2856180A1 (en) 2013-06-13
BR112014013704B1 (pt) 2023-01-31
US9682137B2 (en) 2017-06-20
AU2012350258B2 (en) 2017-03-02
IL232926A0 (en) 2014-07-31
ES2748864T3 (es) 2020-03-18
US20140294880A1 (en) 2014-10-02
JP2018150370A (ja) 2018-09-27
AU2012350258A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
US10946090B2 (en) Consensus/ancestral immunogens
AU2018283811B2 (en) Poxvirus vectors encoding HIV antigens, and methods of use thereof
US8048431B2 (en) Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
CN104169295B (zh) 突变的慢病毒env蛋白及其用作药物的用途
EP3004143B1 (en) Mutated non-primate lentiviral env proteins and their use as drugs
WO2015009946A1 (en) Method of increasing immune response to hiv antigens
US9636396B2 (en) Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
AU2017200429A1 (en) Consensus/Ancestral Immunogens
HK1126146A (en) Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220106

Address after: Paris, FRA

Patentee after: VIROXIS S A/S

Patentee after: Guo Jiakeyanzhongxin

Patentee after: University of Thackeray, Paris

Patentee after: Gustavus Institute

Address before: Paris, FRA

Patentee before: VIROXIS S A/S

Patentee before: Guo Jiakeyanzhongxin

Patentee before: UNIVERSITE PARIS-SUD 11

Patentee before: Gustavus Institute

TR01 Transfer of patent right